Skip to content
Kopra Bio logo

Kopra Bio

Kopra Bio is a YC Summer 2024 (S24) company. Based in San Francisco, CA, USA. Team of 2.

  • Gene Therapy
  • Synthetic Biology
  • Biotech
  • Therapeutics
  • Oncology

About Kopra Bio

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Kopra Bio develops genetically engineered viruses that train the immune system to attack cancer cells. The therapy reprograms cancer cells themselves to produce the signals that drive their own destruction, replacing conventional immunotherapy drugs. The company is targeting glioblastoma, the most aggressive form of brain cancer, first.

Go-to-market

The company is in the preclinical stage, advancing a pipeline built on UCSF-developed technology toward therapeutic candidates for oncology.

From the Y Combinator listing

How Kopra Bio describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Genetically engineered viruses that teach your immune system to kill…

Kopra Bio makes genetically engineered viruses that teach your immune system to kill cancer using tech we developed at UCSF. We’re making the next Keytruda ($25B/yr cancer drug blockbuster) starting with the most aggressive form of brain cancer, glioblastoma. In the most challenging brain cancer model, we improve survival from 0% with the current FDA approved treatment to 90% with our treatment.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
San Francisco, CA, USA
Team size
2
Status
Active
Stage
Early

Founders (1)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works